Calliditas Therapeutics AB

Developing global, high-value products for patients with significant unmet medical needs in niche indications

Find out more about us

Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

IPO

IPO Calliditas Therapeutics

Press releases

Jun 15, 2018Calliditas announces listing on Nasdaq Stockholm and related prospectus
Nov 20, 2017Surrogate marker and design of Calliditas Therapeutics’ IgA nephropathy Phase 3 study agreed with the FDA
Nov 15, 2017Pharmalink is renamed Calliditas Therapeutics

All press releases

Calendar

Aug 16, 2018Interim report for the period January 1 – June 30, 2018
Nov 1, 2018Interim report for the period January 1 – September 30, 2018
Feb 7, 2019Year-end report for the period January 1 – December 31, 2018